FDA lets select AI-driven medical devices reach patients via new pilot program
The FDA has granted provisional market access to four generative-AI medical devices, including those from Cadence and Limbic, through its TEMPO pilot.
The Food and Drug Administration is experimenting with a new regulatory pathway that lets certain generative-AI medical devices enter the market before receiving formal marketing approval. Four devices have been approved for the TEMPO pilot, with Cadence and Limbic among the participating companies. This initiative is designed to increase the number of AI tools eligible for the Medicare ACCESS model, a payment experiment focused on chronic-condition management.
By allowing these products to be sold early, the FDA hopes to gather practical data on how to oversee AI-driven diagnostics and treatment decisions. The pilot also offers developers a chance to refine their technologies while the agency fine-tunes its oversight approach. Stakeholders view the move as a step toward faster patient access to innovative digital health solutions.
Why it matters
It shows how regulators are adapting to AI in healthcare, potentially speeding patient access to new treatments.
In this story
